VIS-101, purpose-designed to be best-in-class for retinal vascular diseases, is a tetravalent, dual VEGF-A X ANG-2 ...

VIS-101 targets VEGF-A and ANG-2 with a bispecific tetravalent format designed to increase ligand affinity and binding capacity, aiming to improve anatomic/visual outcomes and extend dosing intervals.

Outlook Therapeutics, Inc. has announced a key development in the treatment of wet age-related macular degeneration (wet AMD) with the National Institute for Health and Care Excellence (NICE) ...

VIS-101, purpose-designed to be a best-in-class dual VEGF-A/ANG-2 inhibitor, has the potential to provide more effective and ...

Ixo-vec is a potential best-in-class one-time gene therapy designed to deliver long-term efficacy, reduce the burden of frequent anti-VEGF and improve vision outcomes for patients with wet AMD ARTEMIS ...

Please provide your email address to receive an email when new articles are posted on . The tyrosine kinase inhibitor maintained vision at week 36 in the SOL-1 trial. Axpaxli demonstrated positive ...

NovaBridge Biosciences NBP shares are up on Monday following the announcement of positive topline results from the Phase 2a study of VIS-101, a treatment for retinal vascular diseases. Trial Data The ...

Please provide your email address to receive an email when new articles are posted on . Khanani delved into tyrosine kinase inhibitors, including the SOL-1 and SOL-R trials evaluating OTX-TKI ...

ISELIN, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United ...